Niagen Bioscience, Inc. financial data

Symbol
NAGE on Nasdaq
Location
10900 Wilshire Blvd, Suite 600, Los Angeles, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - May 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 325 % +33%
Quick Ratio 57.1 % -13.1%
Debt-to-equity 56.2 % -39.4%
Return On Equity 33.9 %
Return On Assets 21.7 %
Operating Margin 12.3 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 77.8M shares +3.24%
Common Stock, Shares, Outstanding 78.4M shares +4.36%
Entity Public Float 143M USD +76%
Common Stock, Value, Issued 78K USD +4%
Weighted Average Number of Shares Outstanding, Basic 77.8M shares +3.43%
Weighted Average Number of Shares Outstanding, Diluted 83.2M shares +10.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 108M USD +29.8%
Cost of Revenue 40.5M USD +24.7%
Research and Development Expense 5.18M USD -11.6%
Selling and Marketing Expense 30.8M USD +21.9%
General and Administrative Expense 18.2M USD -23.9%
Operating Income (Loss) 13.2M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 5.23M USD
Income Tax Expense (Benefit) 168K USD
Net Income (Loss) Attributable to Parent 14.1M USD
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 55.5M USD +103%
Accounts Receivable, after Allowance for Credit Loss, Current 7.05M USD +6.78%
Inventory, Net 11.2M USD -10.5%
Assets, Current 76.2M USD +55.6%
Operating Lease, Right-of-Use Asset 2.68M USD +20.6%
Intangible Assets, Net (Excluding Goodwill) 322K USD -31.8%
Other Assets, Noncurrent 458K USD +13.1%
Assets 81.3M USD +50.4%
Accounts Payable, Current 10.6M USD +34.6%
Accrued Liabilities, Current 9.05M USD -13.5%
Liabilities, Current 20.8M USD +7.12%
Contract with Customer, Liability, Noncurrent 2.58M USD -22.1%
Operating Lease, Liability, Noncurrent 2.58M USD +9.34%
Liabilities 26M USD +3.44%
Retained Earnings (Accumulated Deficit) -177M USD +7.39%
Stockholders' Equity Attributable to Parent 55.3M USD +91.2%
Liabilities and Equity 81.3M USD +50.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 7.88M USD +2572%
Net Cash Provided by (Used in) Financing Activities 3.11M USD
Net Cash Provided by (Used in) Investing Activities -32K USD +22%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 78.4M shares +4.36%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 11M USD +4465%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 55.6M USD +102%
Deferred Tax Assets, Valuation Allowance 44.3M USD -4.53%
Deferred Tax Assets, Gross 44.7M USD -4.43%
Operating Lease, Liability 3.52M USD +9.64%
Depreciation 158K USD -11.2%
Lessee, Operating Lease, Liability, to be Paid 4.03M USD +12.9%
Operating Lease, Liability, Current 939K USD +10.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 782K USD -13.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.18M USD +4.23%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +14.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 515K USD +41.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 657K USD +33.8%
Deferred Tax Assets, Operating Loss Carryforwards 35.2M USD -4.11%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 338K USD -5.59%
Operating Lease, Payments 295K USD +224%
Additional Paid in Capital 232M USD +5.59%
Amortization of Intangible Assets 37K USD -2.63%
Deferred Tax Assets, Net of Valuation Allowance 386K USD +7.82%